Stockscreener 앱 받기
5.82
0.68%
-0.04
시간 외 거래:
5.83
0.010
+0.17%
Gyre Therapeutics Inc 주식(GYRE)의 최신 뉴스
Gyre Therapeutics (NASDAQ: GYRE) investors back directors, pay and Series B conversion - Stock Titan
Gyre COO Ye Weiguo sells $17,276 in company stock - Investing.com
Gyre Therapeutics (GYRE) COO sells 2,800 shares after exercising options - Stock Titan
GYRE Q1 2026 Earnings: EPS Surprises to the Upside, Revenue Not Reported, Stock SlipsForward EPS Estimate - newsline.com
Gyre Therapeutics COO Ye Weiguo sells $128,885 in stock - Investing.com UK
Gyre Therapeutics COO Ye Weiguo sells $128,885 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics, Inc. (GYRE) reports Q1 loss, lags revenue estimates - MSN
Gyre Therapeutics (GYRE) COO sells 20,918 shares after exercising options - Stock Titan
[Form 4] GYRE THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
CEO of Gyre Therapeutics (NASDAQ: GYRE) receives 120,000 stock options - Stock Titan
GYRE: All proposals passed with sufficient votes and no shareholder questions were raised - TradingView
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Trend Analysis - newsline.com
Gyre therapeutics COO Ye Weiguo sells $218,561 in stock By Investing.com - Investing.com Australia
Gyre therapeutics COO Ye Weiguo sells $218,561 in stock - Investing.com
GYRE (GYRE) COO exercises options, sells 34,976 shares but keeps 700,000 - Stock Titan
RLMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Gyre Therapeutics Updates Post-Cullgen Acquisition Growth Strategy - The Globe and Mail
Gyre updates corporate presentation detailing pipeline, China strategy and regulatory progress - TradingView
Gyre Therapeutics (NASDAQ: GYRE) details F351 liver fibrosis data and degrader programs - Stock Titan
New strong sell stocks for May 27th - MSN
Gyre Therapeutics (GYRE) Gains Momentum: Price Nears Key Resistance at $6.21Equal Weight ETF - The Legal Advocate
Gyre Therapeutics (GYRE) Holds Steady at $5.74, Testing Key Support ZoneInside Day Breakout - The Legal Advocate
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises AnalystsRevenue Guidance Range - The Legal Advocate
China regulator accepts Gyre’s liver fibrosis drug application By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) Declines 3.1% as Stock Tests Key Support Near $5.45Gap Up Stocks - The Legal Advocate
US High Growth Tech Stocks To Watch - simplywall.st
Law firm investigates Gyre Therapeutics for possible securities law violations and breaches of fiduciary duty. - Pluang
Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm - TMX Newsfile
Gyre Therapeutics COO Ye Weiguo sells $45,680 in stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics COO Ye Weiguo sells $45,680 in stock - Investing.com
COO of GYRE Therapeutics (NASDAQ: GYRE) sells shares after option exercises - Stock Titan
New Strong Sell Stocks for May 27th - Yahoo Finance
Gyre Therapeutics Inc. (GYRE) Edges Lower, Testing Key Support LevelsMedian Line - The Legal Advocate
GYRE Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Surprise Amid Revenue AbsenceProfit Margin Analysis - The Legal Advocate
Gyre Therapeutics (GYRE) Falters: Testing Key Support After 1.94% DeclineDividend Growth Stocks - newsline.com
GYRE Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue Stage - Newser
Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale By Investing.com - Investing.com India
Gyre therapeutics COO Ye Weiguo’s $136,653 stock sale - Investing.com
GYRE (GYRE) COO sells 22,220 shares after stock option exercises - Stock Titan
Gyre Therapeutics COO Ye Weiguo sells $59,418 in shares By Investing.com - Investing.com India
Gyre Therapeutics (GYRE) director cancels 250,000-share stock option agreement - Stock Titan
Gyre Therapeutics COO Ye Weiguo sells $59,418 in shares - Investing.com
Gyre Therapeutics (GYRE) COO sells shares after exercising options - Stock Titan
Gyre Therapeutics (GYRE) Stock Analysis: Falls -3.19%, Watching $5.76 2026-05-20Systematic Flow - newsline.com
Gyre Therapeutics (GYRE) Stock: Slides -2.17%, Support at $5.98 2026-05-19Advance Decline Volume - Newser
GYRE (GYRE) COO Ye exercises options and sells 28,680 shares in May - Stock Titan
1.27%
1.43%
자본화:
|
볼륨(24시간):